Chronic kidney disease Urological and Genital Diseases Chronic kidney disease
Conditions
Interventions
Description: 150 subjects for randomisation and n=150 age matched controls
Blood pressure control, Control of clinic systolic blood pressure to target using ACEi therapy as first line agent. Followed
Sponsors
Guy's and St. Thomas' NHS Foundation Trust (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 2 to 15 years 2. Chronic kidney disease with eGFR between 15-90 ml/min/1.73m2 for two consecutive measurements in the last 12 months 3. With or without anti-hypertensive/s medications (irrespective of recent change/s in antihypertensive therapy) 4. Subjects with average clinic systolic BP <50th percentile and on no antihypertensive medication will be eligible as ?CONTROL? subjects only 5. Other ?CONTROL? subjects will include children with normal renal function and blood pressure attending hospital for unrelated medical review or siblings of subjects with CKD 6. Male and female participants
Exclusion criteria
Exclusion criteria: 1. Age 15 years 2. Subjects who have/had an arterio-venous fistulae 3. Subjects who have/had are on dialysis 4. Subjects who have/had a functioning kidney transplant 5. Patients with symptomatic BP or with past history of difficulty to control BP or 6. Patients in whom there is a clinical urgency to treat BP and inclusion in study may result inpossible delay of treatment 7. Patients with arrhythmia or clinical heart failure 8. Patients with known structural cardiac abnormality 9. Subjects on treatment with angiotensin converting enzyme inhibitor (ACEi) or angiotensin receptor blocker (ARB) agents for treatment of proteinuria only or 10. Subjects who are likely to be of clinical concern following up or down titration of BP levels as described in ?Appendix 3? 11. Subjects who are unable or intolerant to performance of study measurements e.g. height, echo or PWV 12. Subjects who have/had intolerance to Angiotensin converting enzyme inhibitors (ACEi) drug/s or have any existing contraindications
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The differences in LV mass between aggressive and standard treatment groups measured at 2 and 4 years | — |
Secondary
| Measure | Time frame |
|---|---|
| Differences in cIMT and PWV measured at 2 and 4 years | — |
Countries
England, United Kingdom
Outcome results
None listed